Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its GelrinC® hydrogel implant, a cell-free device designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure. The product aims to offer an alternative to traditional microfracture and complex cell-based therapies, targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists.
Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled. This positions Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.
For a full corporate profile, visit https://ibn.fm/bpPp6.
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC®, the lead product, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process.
The company aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The implications of a successful commercial launch could significantly change the standard of care for knee cartilage repair, offering a less invasive, faster procedure with potentially superior outcomes compared to existing options like microfracture. For patients, this could mean reduced recovery times and improved pain relief, while for the healthcare system, it could lower costs associated with more complex cell-based therapies.
Forward-looking statements in this article are subject to risks and uncertainties, as detailed in the company's filings with the SEC. The original press release is available at www.newmediawire.com.
